EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Gamma2 Subunit

Ensembl ID : ENSPEMG00000016073
Gene Symbol: GABRG2
3 Cross references
204 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Pi Subunit

Ensembl ID : ENSPEMG00000008255
Gene Symbol: GABRP
3 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

Ensembl ID : ENSPEMG00000024127
Gene Symbol: GABRQ
3 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPEMG00000016774
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b-Like

Ensembl ID : ENSPEMG00000017166
Gene Symbol: LOC102923315
2 Cross references
190 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSPEMG00000014106
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSPEMG00000018876
Gene Symbol: GCGR
3 Cross references
183 Possible Orthologues:

Glucagon-Like Peptide 1 Receptor

Ensembl ID : ENSPEMG00000014524
Gene Symbol: GLP1R
1 Cross references
133 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSPEMG00000016104
Gene Symbol: GLP2R
1 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSPEMG00000001040
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosidase Alpha, Acid

Ensembl ID : ENSPEMG00000016108
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Glucosylceramidase Beta

Ensembl ID : ENSPEMG00000009373
Gene Symbol: GBA
3 Cross references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).